C-reactive protein and fibrinogen levels as determinants of recurrent preeclampsia: A prospective cohort study

Journal of Hypertension

Volumn 32, Issue 2, 2014, Pages 408-414

  Van Rijn, Bas B ^a,b   Veerbeek, Jan H ^a   Scholtens, Lenneke C ^a   Uiterweer, Emiel D Post ^a   Koster, Maria P ^a   Peeters, Louis L ^a   Koenen, Steven V ^a   Bruinse, Hein W ^a   Franx, Arie ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

C reactive protein; fibrinogen; lipids; pre pregnancy; preeclampsia; recurrence risk

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREMATURE LABOR; PRIMIPARA; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FIBRINOGEN; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFLAMMATION MEDIATORS; LABOR, INDUCED; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS;

EID: 84893008420     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000027     Document Type: Article

References (35)

1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Preeclampsia. Lancet 2010; 376:631-644.
2. Hernandez-Diaz S, Toh S, Cnattingius S. Risk of preeclampsia in first and subsequent pregnancies: prospective cohort study. BMJ 2009; 338:b2255.
3. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335:974.
4. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet 2001; 357:2002-2006.
5. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after preeclampsia: population based cohort study. BMJ 2001; 323:1213-1217.
6. Kaaja RJ, Greer IA. Manifestations of chronic disease during pregnancy. JAMA 2005; 294:2751-2757.
7. Romundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation 2010; 122:579-584.
8. Rodie VA, Freeman DJ, Sattar N, Greer IA. Preeclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis 2004; 175:189-202.
9. van Rijn BB, Franx A, Steegers EA, de Groot CJ, Bertina RM, Pasterkamp G, et al. Maternal TLR4 and NOD2 gene variants, pro-inflammatory phenotype and susceptibility to early-onset preeclampsia and HELLP syndrome. PLoS One 2008; 3:e1865.
10. Veltman-Verhulst SM, van Rijn BB, Westerveld HE, Franx A, Bruinse HW, Fauser BC, et al. Polycystic ovary syndrome and early-onset preeclampsia: reproductive manifestations of increased cardiovascular risk. Menopause 2010; 17:990-996.
11. van Kuijk SM, Nijdam ME, Janssen KJ, Sep SJ, Peeters LL, Delahaije DH, et al. A model for preconceptional prediction of recurrent early-onset preeclampsia: derivation and internal validation. Reprod Sci 2011; 18:1154-1159.
12. van Rijn BB, Nijdam ME, Bruinse HW, Roest M, Uiterwaal CS, Grobbee DE, et al. Cardiovascular disease risk factors in women with a history of early-onset preeclampsia. Obstet Gynecol 2013; 121:1040-1048.
13. von Dadelszen P, Magee LA, Roberts JM. Subclassification of pree-clampsia. Hypertens Pregnancy 2003; 22:143-148.
14. Skjaerven R, Wilcox AJ, Klungsoyr K, Irgens LM, Vikse BE, Vatten LJ, et al. Cardiovascular mortality after preeclampsia in one child mothers: prospective, population based cohort study. BMJ 2012; 345:e7677.
15. Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol 2009; 114:961-970.
16. Schaaf JM, Bruinse HW, van der Leeuw-Harmsen L, Groeneveld E, Koopman C, Franx A, et al. Reproductive outcome after early-onset preeclampsia. Hum Reprod 2011; 26:391-397.
17. Sikkema JM, Franx A, Bruinse HW, van der Wijk NG, de Valk HW, Nikkels PG. Placental pathology in early onset preeclampsia and intra-uterine growth restriction in women with and without thrombophilia. Placenta 2002; 23:337-342.
18. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX-XIV.
19. van Runnard Heimel PJ, Huisjes AJ, Franx A, Koopman C, Bots ML, Bruinse HW. A randomised placebo-controlled trial of prolonged prednisolone administration to patients with HELLP syndrome remote from term. Eur J Obstet Gynecol Reprod Biol 2006; 128:187-193.
20. Visser GH, Eilers PH, Elferink-Stinkens PM, Merkus HM, Wit JM. New Dutch reference curves for birthweight by gestational age. Early Hum Dev 2009; 85:737-744.
21. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
22. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297:611-619.
23. Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular bio-markers in women. JAMA 2006; 295:1412-1419.
24. van Rijn BB, Hoeks LB, Bots ML, Franx A, Bruinse HW. Outcomes of subsequent pregnancy after first pregnancy with early-onset pree-clampsia. Am J Obstet Gynecol 2006; 195:723-728.
25. Dutch Heart Foundation. Facts and figures. Annual Report 2010. http://www.hartstichting.nl/professionals/cijfers/.
26. Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE, et al. Short-and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension 2004; 44:708-714.
27. Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R. Obesity and preeclampsia: the potential role of inflammation. Obstet Gynecol 2001; 98 (5 Pt 1):757-762.
28. Worns MA, Victor A, Galle PR, Hohler T. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels: a study in twins. Genes Immun 2006; 7:600-605.
29. de Maat MP, Bladbjerg EM, Hjelmborg J, Bathum L, Jespersen J, Christensen K. Genetic influence on inflammation variables in the elderly. Arterioscler Thromb Vasc Biol 2004; 24:2168-2173.
30. Visser N, van Rijn BB, Rijkers GT, Franx A, Bruinse HW. Inflammatory changes in preeclampsia: current understanding of the maternal innate and adaptive immune response. Obstet Gynecol Surv 2007; 62:191-201.
31. Souwer ET, Blaauw J, Coffeng SM, Smit AJ, Van Doormaal JJ, Faas MM, et al. Decreased arterial elasticity in formerly early-onset preeclamptic women. Acta Obstet Gynecol Scand 2011; 90:797-801.
32. Kvehaugen AS, Dechend R, Ramstad HB, Troisi R, Fugelseth D, Staff AC. Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsia. Hypertension 2011; 58:63-69.
33. Veltman-Verhulst SM, van Rijn BB, Westerveld HE, Franx A, Bruinse HW, Fauser BC, et al. Polycystic ovary syndrome and early-onset preeclampsia: reproductive manifestations of increased cardiovascular risk. Menopause 2010; 17:990-996.
34. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
35. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380:565-571.